Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma

Sponsor
Nordic Lymphoma Group
Study ID
NCT03505944
Phase
PHASE1/PHASE2
Status
Unknown

Conditions

  • Relapsed Non Hodgkin Lymphoma

Eligibility Criteria

Sex
ALL
Age
19 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Venetoclax — DRUG
    venetoclax + lenalidomide + rituximab

Study Details

Phase I/II trial, with the aim of evaluating the efficacy of venetoclax to the backbone of rituximab-lenalidomide in patients with relapsed/refractory MCL.

Key Dates

Start date
Jul 1, 2018
Status verified
Oct 2021
Primary completion
Dec 1, 2022
Completion
Dec 1, 2022

Study Design

Enrollment
59 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment
    Venetoclax+lenalidomide+rituximab

Primary Outcome Measure

Overall response rate [ Time Frame: 6 months ]

Related Studies